https://www.live-feeds.com/feed/under-the-radar-kodiak-stock-surges-as-eye-drug-matches-regeneron-sContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/under-the-radar-kodiak-stock-surges-as-eye-drug-matches-regeneron-shttps://www.live-feeds.com/feed/under-the-radar-kodiak-stock-surges-as-eye-drug-matches-regeneron-s#u95653Fri, 02 Oct 2026 23:05:16 +0000Kodiak Sciences' stock has surged up to 178% after its eye disease drugs, Zenkuda and tabirafusp-ted, matched Regeneron's Eylea in a phase 3 trial for wet age-related macular degeneration. The drugs met the primary endpoint of vision improvement at one year, with Zenkuda showing 7.2 letters improvement versus 7.6 for Eylea. Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.Why it mattersKodiak Sciences' successful phase 3 trial results position the company as a significant competitor to Regeneron's blockbuster drug Eylea in